Refining in-vivo models of pulmonary fibrosis

QR Code

Refining in-vivo models of pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with limited treatment options. IPF is characterized by excessive collagen deposition within the lung resulting in loss of lung function and a survival rate worse than most cancers. There is an urgent need to develop and better characteris...

Full description

Bibliographic Details
Main Author:	Habgood, Anthony
Format:	Thesis (University of Nottingham only)
Language:	English
Published:	2018
Subjects:	Pulmonary fibrosis; Animal models; Lung fibrosis; Ex vivo models; SLPI
Online Access:	https://eprints.nottingham.ac.uk/55561/

Similar Items

International comparative epidemiology of idiopathic pulmonary fibrosis
by: Hutchinson, John
Published: (2017)

Building an ex vivo model of breast cancer lung metastasis
by: Grey, James F.E.
Published: (2019)

Preparation of potent and selective αvβ6 integrin inhibitors for the treatment of idiopathic pulmonary fibrosis and synthetic approaches towards the total synthesis of mescengricin
by: Robinson, Henry Duncan
Published: (2021)

Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
by: Hutchinson, John P., et al.
Published: (2015)

Evaluation of activity limitation in patients with idiopathic pulmonary fibrosis grouped according to Medical Research Council Dyspnea Grade
by: Kozu, R., et al.
Published: (2014)

Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century
by: Hutchinson, John P., et al.
Published: (2014)

The role of Interleukin-33 in the development of idiopathic pulmonary fibrosis
by: Stephenson, Katherine
Published: (2021)

Interplay between EZH2 and G9a regulates CXCL10 gene repression in idiopathic pulmonary fibrosis
by: Coward, William R., et al.
Published: (2017)

Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF)
by: Barratt, Shaney L., et al.
Published: (2018)

Investigations into novel small molecules as potential treatments for idiopathic pulmonary fibrosis and malaria
by: Park, Jozef
Published: (2022)

The role of mesenchymal G proteins in pulmonary fibrosis and lung development
by: Goodwin, Amanda T.
Published: (2021)

The role of galectin-3 in the development of idiopathic pulmonary fibrosis
by: Parmar, Nimesh
Published: (2019)

cAMP mediated regulation of fibroblast to myofibroblast differentiation in idiopathic pulmonary fibrosis
by: Wright, Rebecca
Published: (2016)

Hyperpolarized noble gas magnetic resonance imaging of the ex vivo rodent lung
by: Lilburn, D.M.L.
Published: (2015)

Surgical lung biopsy for the diagnosis of interstitial lung disease in England: 1997-2008
by: Hutchinson, John P., et al.
Published: (2016)

Application of a human primary epithelial-fibroblast co-culture system to study fibrosis
by: Richardson, Jaineeta
Published: (2017)

In vitro modelling of respiratory infections in idiopathic pulmonary fibrosis (IPF) using human induced pluripotent stem cell (hiPSCs)-derived alveolar epithelial type II cells
by: Serna Valverde, Ana Lilia
Published: (2023)

Biomarkers of progressive lung fibrosis
by: Khan, Fasihul
Published: (2022)

Measures of body habitus are associated with lung function in adults with cystic fibrosis: a population-based study
by: Forrester, Doug L., et al.
Published: (2013)

Prevention of treatment related adverse effects in cystic fibrosis
by: Jain, Kamini
Published: (2018)

The potential therapeutic effect of manipulating the extracellular matrix in idiopathic pulmonary fibrosis
by: Philp, Christopher J.
Published: (2016)

The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: a randomised comparison
by: Prayle, A.P., et al.
Published: (2015)

Spatiotemporal regulation of anti-remodelling signalling pathways in primary human lung fibroblasts
by: Roberts, Maxine
Published: (2020)

Structure activity relationships of αv integrin antagonists for pulmonary fibrosis by variation in aryl substituents
by: Adams, James, et al.
Published: (2014)

Suberoylanilide hydroxamic acid – a potential epigenetic therapeutic agent for lung fibrosis?
by: Wang, Z., et al.
Published: (2009)

Effects of cigarette smoke on killer cell activation in chronic obstructive pulmonary disease
by: Wang, Jia
Published: (2015)

Defining the mechanism of galectin-3-mediated TGF-β1 activation and its role in lung fibrosis
by: Calver, J.F.
Published: (2023)

Glutamine supplementation in cystic fibrosis: a randomized placebo-controlled trial
by: Forrester, Doug L., et al.
Published: (2015)

Delayed publications of clinical trials in cystic fibrosis
by: Hurley, M.N., et al.
Published: (2011)

The inhibition of human lung fibroblast proliferation and differentiation by Gs-coupled receptors is not predicted by the magnitude of cAMP response
by: Roberts, Maxine J., et al.
Published: (2018)

European Cystic Fibrosis Society standards of care: best practice guidelines
by: Smyth, Alan R., et al.
Published: (2014)

Xbox Kinect™ represents high intensity exercise for adults with cystic fibrosis
by: Holmes, H., et al.
Published: (2013)

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis
by: Hurley, M.N., et al.
Published: (2012)

Early respiratory bacterial detection and anti-staphylococcal antibiotic prophylaxis in young children with cystic fibrosis
by: Hurley, Matthew, et al.
Published: (2017)

High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection
by: Monaghan, Tanya M., et al.
Published: (2017)

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C
by: Thabet, Khaled, et al.
Published: (2016)

The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and health care providers
by: Rowbotham, Nicola J., et al.
Published: (2017)

Understanding the Costs of Care for Cystic Fibrosis: an Analysis by Age and Health State
by: Van Gool, K., et al.
Published: (2013)

Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia
by: Norman, Richard, et al.
Published: (2012)

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients
by: Elborn, J. Stuart, et al.
Published: (2015)